Deals
Allergan CEO Pushes for Trump to Lead Drug Price Discussions
- Saunders points to JFK’s tactics to hold down steel costs
- Drugmaker looks for smaller takeover targets, no megadeals
Brent Saunders
Photographer: Scott Eells/BloombergThis article is for subscribers only.
To satisfy the Trump administration’s calls to deal with high U.S. drug costs, one industry leader is proposing that the president lead negotiations with drugmakers to restrain prices.
Allergan Plc Chief Executive Officer Brent Saunders cited tactics used by President John F. Kennedy decades ago to keep down steel prices. The administration also could waive federal antitrust rules that currently prohibit drugmakers from discussing pricing so they could put together guidelines to follow, he said.